A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
NCT00502840
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
193
Enrollment
INDUSTRY
Sponsor class
Conditions
Rheumatoid Arthritis
Interventions
DRUG:
rituximab [MabThera/Rituxan]
Sponsor
Hoffmann-La Roche